OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-n ...

FDA IND follows promising Phase 2 results presented at 2024 ASCO GI revealing that the addition of HLX22 (AC101) to biosimilar trastuzumab a ...

Next-generation CD40 agonists have opportunity to address key biological and medical needs in immuno-oncology Bispecific CD40-targeting anti ...

Study conducted by Moores Cancer Center at University of California San Diego to evaluate safety and efficacy of mitazalimab injected intrat ...

1st Presentation supports dosing regimen for mitazalimab in combination with FOLFORINOX and improvement of antitumor response 2nd Presentati ...

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the publication of a scientific article featuring its no ...